Study of second-line treatment for thyroid eye disease
Part of Eyes & vision, Hormones & metabolism, Immune system & allergy clinical trials.
This trial looks at how thyroid eye disease (inflammation behind the eyes) changes over time in people who need stronger treatments after steroids haven't worked well enough. It aims to better understand the disease and how different second-line treatments may help.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with moderate to severe thyroid eye disease.
- Your thyroid hormone levels are being managed by an endocrinologist to be stable.
- You have tried at least 3 weeks of high-dose steroids but your eye symptoms did not improve enough.
- Your eye symptoms got worse (score of 3 or more) when reducing or stopping steroids.
- You are about to start or have started immunotherapy, biotherapy, or radiation therapy as a second treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different ways of giving a steroid medicine called methylprednisolone through an IV to treat thyroid eye disease (also called Graves orbitopathy), which causes bulging and inflammation of the eyes. The goal is to see which schedule works better and has fewer side effects.
This trial tests whether atorvastatin, a cholesterol-lowering drug, can improve symptoms of thyroid eye disease (Graves' orbitopathy). It is for people with moderate-to-severe, active eye disease who have not recently used steroids or other treatments for it.
This study aims to build a model that helps doctors predict how thyroid eye disease (TAO) will progress, specifically for patients with moderate to severe symptoms. If you have had TAO and meet the activity criteria, your participation could lead to better personalized care.
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
This trial tests whether targeted radiation to the eyes can help reduce the inflammation and symptoms of Graves' eye disease (also called thyroid eye disease). It is for people who have had eye symptoms for less than a year and whose eyes are still actively inflamed.
This trial tests a two-step treatment for active, moderate-to-severe thyroid eye disease (TAO). You will first receive hormone therapy, followed by a drug called IBI311. The goal is to see if this sequence works better for people who have not had steroid treatment before.
Hear when a new Basedow Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.